Single-Cell Dosimetry for Radioimmunotherapy of B-Cell Lymphoma Patients with Special Reference to Leukemic Spread
- 1 June 2007
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 22 (3) , 357-366
Abstract
Aims: Many lymphoma patients have both macroscopic tumors and single-cell manifestations of their disease. Treatment efficacy could, therefore, depend on the radionuclide used. The aim of this study was to investigate dosimetry at a cellular level for three isotopes of radioiodine. Methods: Cells were assumed to be spherical with radii of 6.35, 7.7, and 9.05 μm corresponding to the dimensions of the Raji cells. The radius of the nucleus was assumed to be 75% of the cellular radius. The electron energies were 18, 28, and 190 keV, corresponding to the mean electron energy per decay for 125I, 123I, and 131I, respectively. S-values for different activity distributions were simulated using Monte Carlo and dose-volume histograms as well as absorbed doses, and absorbed dose rates were calculated. Results: 125I gives the highest absorbed dose (∼4–40 times that of 131I), whereas 123I will give the highest absorbed dose rate (∼100 times that of 131I). Under the given assumptions, the absorbed dose at this level is more dependent on the size of the cells than on whether the radioimmunoconjugate is internalized. Conclusions: This enquiry showed that both 123I and 125I have greater potential than 131I for the treatment of leukemic spread in patients with lymphoma.Keywords
This publication has 21 references indexed in Scilit:
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaNew England Journal of Medicine, 2005
- Monte Carlo simulation of the energy loss of low-energy electrons in liquid waterPhysics in Medicine & Biology, 2003
- Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- A Monte Carlo track structure code for electrons (~10 eV-10 keV) and protons (~0.3-10 MeV) in water: partitioning of energy and collision eventsPhysics in Medicine & Biology, 2000
- Response criteria for NHL: Importance of ‘normal’ lymph node size and correlations with response ratesAnnals of Oncology, 2000
- Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodiesInternational Journal of Cancer, 1999
- Microdosimetry and radiocurability: modelling targeted therapy with -emittersPhysics in Medicine & Biology, 1996
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of Clinical Oncology, 1996
- Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell LymphomaHybridoma, 1994
- Flow cytometric light chain analysis of peripheral blood lymphocytes in patients with non-Hodgkin's lymphomaBritish Journal of Cancer, 1985